

June 11, 2014



**Amarantus**  
BioScience

## **Amarantus and Brewer Sports Add Partnership With Cavendish Global to #C4CT Alzheimer's Concussion Awareness Summit at United Nations**

MINNEAPOLIS, SAN FRANCISCO and GENEVA, June 11, 2014 (GLOBE NEWSWIRE) -- [Amarantus Bioscience Holdings, Inc.](#) (OTCQB:AMBS) and [Brewer Sports International \(BSI\)](#), today announced the addition of Cavendish Global as partner at the 3<sup>rd</sup> #C4CT (*Coalition for Concussion Treatment*) *Concussion Awareness Summit*, on Thursday, July 31, 2014 at the United Nations in New York City, NY. The summit will be focused on the emerging hypothesis that brain injury may increase the risk of Alzheimer's disease.

Cavendish Global provides family offices and their foundations with a discrete, peer-to-peer knowledge expansion and relationship building environment, combined with the innovative resources required to help develop and implement their individual pro-social impact investment, grant making and philanthropy programs within health and the life sciences.

Mr. Michael Moffat, Cavendish co-founder and President explains, "Brain disorders affect more than 60 million Americans, that's more than one in four Americans suffering from mental illness or brain injury. From autism and Alzheimer's disease to traumatic brain injury (TBI) and post-traumatic stress (PTS), brain ailments cost the U.S. close to \$1 trillion each year. Leading scientists have uncovered compelling evidence of the link between Traumatic Brain Injuries and Alzheimer's and Parkinson's disease." Moffat emphasizes, "Cancer and heart disease affect fewer people, yet receive three times more funding support than brain diseases. With recent advances in understanding the link between TBI and brain ailments, there has never been a better time for pro-social family offices and foundations to make a real difference by accelerating the development of new diagnostics and treatments through increased grant-giving and philanthropy in this important area. Cavendish is committed to help make this happen."

To register or for additional information, please visit [www.c4ctsummit.com](http://www.c4ctsummit.com). For further questions, please contact Lindsay Lommel at [lindsay.lommel@thebrewergroup.com](mailto:lindsay.lommel@thebrewergroup.com).

For sponsorship information please visit: <http://www.c4ctsummit.com/sponsorship-opportunities>.

### **About Cavendish Global**

Cavendish Global consists of over 150 leading family offices and foundations from around the world with combined assets of over \$190 billion who share a passion for pro-social endeavors within health and the life sciences. Cavendish provides family offices with a

number of innovative resources, which includes Cavendish Impact Forums. A unique gathering of leading family offices, Cavendish Impact Forums take place three times each year; in the United States in May, Europe (London, November 2014) and a third event held at a Cavendish Host Partner City which moves to a different global location each year (Dubai, UAE January 2015). The Cavendish Global Health Impact Forum provides family offices with a discrete, peer-to-peer knowledge expansion and relationship building environment, combined with the information and educational resources required by foundations actively seeking to accelerate technological innovation and health access through sustainable philanthropy, grant-making, and impact investing. The Forum is also an opportunity for family offices to champion and share information on projects and organizations, which they are passionate about with other family offices from around the world. Cavendish Global Forums are organized together with the Global Partnerships Forum and the New York Academy of Sciences.

For more information: <http://cavendishglobal.com>.

### **About Amaranthus BioScience Holdings, Inc.**

Amarantus BioScience Holdings (AMBS) is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfolding-related apoptosis. AMBS has licensed Eltoprazine ("Eltoprazine"), a phase 2b ready indication for Parkinson's Levodopa induced dyskinesia and Adult ADHD. AMBS has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro Test(R)") for Alzheimer's disease and owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. AMBS also owns intellectual property for the diagnosis of Parkinson's disease ("NuroPro") and the discovery of neurotrophic factors ("PhenoGuard"). Amaranthus operations are located at Janssen Labs @QB3 in San Francisco, CA. For further information please visit [www.Amarantus.com](http://www.Amarantus.com), or connect with the Company on [Facebook](#), [LinkedIn](#), [Twitter](#) and [Google+](#).

### **About Brewer Sports International**

Brewer Sports International (BSI) is a multi-faceted sports advisory firm within The Brewer Group Companies with a focus on the business of sports, wellness and media for professional athletes, sports agencies, public and private corporations and various partners including international organizations, governments and NGOs. Jack Brewer, five-year National Football League (NFL) veteran and former three-team captain, launched BSI in Minneapolis and expanded to New York, Dallas, Miami, Beijing and Malawi. BSI offers a unique financial services platform to professional athletes and sports agencies, as well as high-net-worth individuals and businesses related to professional sports. BSI takes pride in enabling its clients to capitalize on the endless opportunities presented through sport. For more information, please visit [www.brewersports.com](http://www.brewersports.com) or follow them on [Facebook](#), [Twitter](#) and [LinkedIn](#).

### **About #C4CT**

The Coalition for Concussion Treatment (#C4CT) was founded in 2012 by former NFL player Jack Brewer, CEO of Brewer Sports International and Gerald Commissiong, President and CEO at Amaranthus BioScience Holdings, Inc. with the goal of bringing together those who

are directly affected by TBI-induced neurodegenerative diseases with world class researchers, scientists, and industry leaders whom are actively working towards identifying and developing innovative TBI treatment opportunities. #C4CT serves as a platform to spread awareness about concussions and the severe effects of Traumatic Brain Injury (TBI). #C4CT fosters the critical discussions and partnerships needed to enhance research, treatment efforts, and prevention through a global campaign uniting people who are passionate about the cause.

CONTACT: Cavendish Global:  
Michael Moffat  
Co-founder and President Family Office Relations  
607.437.0966  
michael.moffat@cavenidshglobal.com

Amarantus Bioscience Holdings, Inc.:  
Aimee Boutcher, Director of Investor Relations  
408.737.2734 x 101  
ir@amarantus.com

Brewer Sports International:  
Kristi Hofacker, Interactive Marketing and Media Manager  
651.247.4460  
kristi.hofacker@thebrewergroup.com

Source: Amarantus BioScience Holdings, Inc.